| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Merck & Co., Inc. | EVP, General Counsel | Common Stock | 68,916 | $8,211,453 | $119.15 | 09 Feb 2026 | Direct |
| REGENXBIO Inc. | Director | Common Stock | 22,064 | $175,850 | $7.97 | 30 May 2025 | Direct |
| REGENXBIO Inc. | Director | Stock Options (Right to Buy) | 39,815 | 30 May 2025 | Direct | ||
| REGENXBIO Inc. | Director | Stock Options (Right to Buy) | 24,454 | 31 May 2024 | Direct | ||
| Merck & Co., Inc. | EVP, General Counsel | Restricted Stock Unit | 8,854 | 29 Apr 2025 | Direct | ||
| Merck & Co., Inc. | EVP, General Counsel | Stock Option (Right to Buy) | 0 | 09 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 09 Feb 2026 | 9 | $0 | 4 | EVP, General Counsel | 09 Feb 2026, 16:01 |
| MRK | Merck & Co., Inc. | 26 Jan 2026 | 1 | +$1,244,014 | 4 | EVP, General Counsel | 28 Jan 2026, 16:19 |
| RGNX | REGENXBIO Inc. | 30 May 2025 | 2 | $0 | 4 | Director | 03 Jun 2025, 16:33 |
| MRK | Merck & Co., Inc. | 29 Apr 2025 | 2 | $0 | 4 | EVP, General Counsel | 01 May 2025, 18:03 |
| MRK | Merck & Co., Inc. | 27 Jan 2025 | 1 | +$2,489,929 | 4 | EVP, General Counsel | 29 Jan 2025, 18:29 |
| RGNX | REGENXBIO Inc. | 31 May 2024 | 2 | $0 | 4 | Director | 04 Jun 2024, 16:43 |
| MRK | Merck & Co., Inc. | 30 Apr 2024 | 1 | $0 | 4 | EVP, General Counsel | 02 May 2024, 16:19 |
| MRK | Merck & Co., Inc. | 02 Feb 2024 | 3 | -$4,593,558 | 4 | EVP, General Counsel | 02 Feb 2024, 16:05 |
| MRK | Merck & Co., Inc. | 22 Jan 2024 | 1 | +$2,782,480 | 4 | EVP, General Counsel | 24 Jan 2024, 16:11 |
| RGNX | REGENXBIO Inc. | 02 Jun 2023 | 2 | $0 | 4 | Director | 06 Jun 2023, 17:11 |
| MRK | Merck & Co., Inc. | 04 May 2023 | 1 | -$2,250,834 | 4 | EVP, General Counsel | 05 May 2023, 17:13 |
| MRK | Merck & Co., Inc. | 02 May 2023 | 1 | $0 | 4 | EVP, General Counsel | 04 May 2023, 17:34 |
| MRK | Merck & Co., Inc. | 03 Feb 2023 | 3 | -$3,555,329 | 4 | EVP, General Counsel | 06 Feb 2023, 15:21 |
| MRK | Merck & Co., Inc. | 23 Jan 2023 | 1 | +$1,717,534 | 4 | EVP, General Counsel | 25 Jan 2023, 16:03 |
| MRK | Merck & Co., Inc. | 28 Oct 2022 | 8 | -$16,422,893 | 4 | EVP, General Counsel | 01 Nov 2022, 16:28 |
| RGNX | REGENXBIO Inc. | 03 Jun 2022 | 2 | $0 | 4 | Director | 07 Jun 2022, 16:26 |
| RGNX | REGENXBIO Inc. | 03 Jun 2022 | 0 | $0 | 3 | Director | 07 Jun 2022, 16:24 |
| MRK | Merck & Co., Inc. | 03 May 2022 | 1 | $0 | 4 | EVP, General Counsel | 05 May 2022, 17:17 |
| MRK | Merck & Co., Inc. | 24 Feb 2022 | 1 | +$1,354,054 | 4 | EVP, General Counsel | 28 Feb 2022, 15:35 |